Full-profile pharmacokinetics, anticancer activity and toxicity of an extended release trivalent PEGylated irinotecan prodrug

Irinotecan is an anticancer topoisomerase I inhibitor that acts as a prodrug of the active metabolite, SN-38. Unfortunately, the limited utility of irinotecan is attributed to its pH-dependent stability, short half-life and dose-limiting toxicity. To address this problem, a novel trivalent PEGylated...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shiwen Song, Dong Sun, Hong Wang, Jinliang Wang, Huijing Yan, Xuan Zhao, John Paul Fawcett, Xin Xu, Deqi Cai, Jingkai Gu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2023-08-01
coleção:	Acta Pharmaceutica Sinica B
Assuntos:	Irinotecan SN-38 Trivalent PEGylated irinotecan Prodrug Full-profile pharmacokinetics
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2211383523000114
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!